Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Strattera
Synonyms :
atomoxetine
Class :
Selective norepinephrine reuptake inhibitors
Brand Name :
Strattera
Synonyms :
atomoxetine
Class :
Selective norepinephrine reuptake inhibitors
Dosage Forms & Strengths
Capsule, Oral:
10 mg
18 mg
25 mg
40 mg
60 mg
80 mg
100 mg
Attention Deficit Hyperactivity Disorder (ADHD)
40
mg
Orally
once a day
Increase after 3 days to 40 mg twice a day (at the morning and night)
10
mg
Orally
twice a day
and increase to 18 mg twice a day if needed
Attention-deficit/hyperactivity Disorder (ADHD)
40
mg
Capsule
Orally
once a day
increase the dose to 80 mg after 3 days
No safe and efficacious dosing is available
Attention-deficit/hyperactivity Disorder (ADHD)
40
mg
Capsule
Orally
once a day
increase the dose to 80 mg after 3 days
Refer to adult dosing
when both drugs are combined, there may be an increase in qtc interval
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with astemizole
may have an increased QTc-prolonging effect when combined with bedaquiline
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with chlorpromazine
may have an increased QTc-prolonging effect when combined with cisapride
may have an increased QTc-prolonging effect when combined with clofazimine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with clozapine
may have an increased QTc-prolonging effect when combined with dasatinib
May enhance the QTc-prolonging effect of each other when combined
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
inotuzumab: they may enhance the QTc-prolonging effect of QTc-prolonging agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
amiodarone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pilsicainide HCL: they may increase the QTc-prolonging effect of QTc-prolonging Agents
darunavir: it may increase the risk or severity of QTc prolongation
QTc interval increases on taking atomoxetine and lenvatinib together. Avoid or take an alternate drug
when both drugs are combined, there may be an increase in the QTC interval
it increases the toxicity of norepinephrine reuptake inhibitors
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of Norepinephrine Reuptake Inhibitors
may have an increased QTc-prolonging effect when combined with flupentixol
may have an increased QTc-prolonging effect when combined with levoketoconazole
It may enhance QTc interval when combined with pentamidine
it increases the toxicity of norepinephrine reuptake inhibitors
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
it increases the effect of Norepinephrine Reuptake Inhibitors
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
thiazide and it’s like diuretics increase the effect of QTc prolongation
it increases the toxicity of norepinephrine reuptake inhibitors
May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
they increase the effect of Norepinephrine Reuptake Inhibitors
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
piperaquine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
may increase the tachycardic effect of atomoxetine
may increase the tachycardic effect of atomoxetine
may increase the tachycardic effect of atomoxetine
may increase the tachycardic effect of atomoxetine
may increase the tachycardic effect of atomoxetine
may have an increased hypertensive effect when combined with sympathomimetics
may have an increased hypertensive effect when combined with sympathomimetics
may have an increased tachycardic effect when combined with beta2-agonists
may have an increased tachycardic effect when combined with beta2-agonists
may have an increased tachycardic effect when combined with beta2-agonists
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
atomoxetine: they may increase the tachycardic effect of Beta2-Agonists
atomoxetine: they may increase the tachycardic effect of Beta2-Agonists
atomoxetine: they may increase the tachycardic effect of Beta2-Agonists
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
when ajmaline is used together with atomoxetine, the risk or seriousness of QTc prolongation is enhanced
atomoxetine has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
atomoxetine: they may increase the stimulatory effect of antihistamines
atomoxetine: they may increase the stimulatory effect of antihistamines
atomoxetine: they may increase the stimulatory effect of antihistamines
atomoxetine: they may increase the stimulatory effect of antihistamines
atomoxetine: they may increase the stimulatory effect of antihistamines
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
When ponesimod is used together with atomoxetine, this leads to enhanced risk or seriousness of bradycardia
When atomoxetine is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When atomoxetine is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
atomoxetine leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of atomoxetine which leads to increased level of serum
atomoxetine leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
atomoxetine leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
atomoxetine leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
atomoxetine leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
atomoxetine leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When indisulam is used together with atomoxetine, this leads to a reduction in atomoxetine metabolism
the hazard or seriousness of QTc prolongation can be heightened when atomoxetine is combined with digitoxin
atomoxetine may decrease the excretion rate of almasilate, leading to higher serum levels
When atomoxetine is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
when both drugs are combined, both increase the QTC interval
when both drugs are combined, there may be an increased QTC interval
May increase the tachycardic effect (hypertension)
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
may increase the hypertension effect of sympathomimetic drugs
may increase the hypertension effect of sympathomimetic drugs
hydrocodone/chlorpheniramine/pseudoephedrine
may increase the hypertensive effect of sympathomimetic drugs
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may increase the tachycardic effect of beta2 agonists
may increase the tachycardic effect of beta2 agonists
may increase the risk or severity of hypertension when combined
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
may increase the hypertensive effect of Sympathomimetics
may increase the QTc-prolonging effect when combined
may increase the QTc-prolonging effect of each other when combined
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with fluorouracil products
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with ondansetron
may have an increased QTc-prolonging effect when combined with pentamidine
hydroxyzine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pacritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
adverse effects or toxic effects of lacosamide are increased by antiarrhythmic agents when used in combination
the tachycardic activity of racepinephrine may be increased
the antihypertensive activity of Remikiren may be reduced
When atomoxetine is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
amitriptyline: it may increase the risk or severity of QTc prolongation agents
benserazide: it may increase the risk or severity of QTc prolongation agents
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
it increases the effect of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
it increases the effect of norepinephrine reuptake inhibitors
Frequency defined:
>10%
Increased diastolic blood
Abdominal pain
Constipation
Erectile dysfunction
Drowsiness
Insomnia
1% to 10%
Palpitations
Syncope
Tachycardia
Excoriation of skin
Anorexia
Dyspepsia
Dysmenorrhea
Dysuria
Abnormal dreams
Blurred vision
Mydriasis
Pregnancy consideration: limited use in pregnancy is reported for the treatment of ADHD.
Lactation: excretion of atomoxetine in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Atomoxetine
Pronounced: atomoxetine
Why do we use atomoxetine?
Atomoxetine is used for the treatment of ADHD and orthostatic hypotension.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
